Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CAMZYOS (mavacamten) is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive HCM.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Camzyos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
Following initial efforts focused on multiple sclerosis (MS), PicnicHealth, Roche and Genentech recently expanded their collaboration to support Huntington’s disease (HD), paroxysmal nocturnal hemoglobinuria (PNH), and hemophilia.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 17, 2020